top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

CRVS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 31.30%

Insider Buying (Last 12 Months): $24,500.00

Insider Selling (Last 12 Months): $0.00

Corvus Pharmaceuticals Insider Trading History Chart

Corvus Pharmaceuticals Share Price & Price History

^$1.45

▼ -0.06 (-3.97%)

As of 04/25/2024 11:19 AM ET

Days: 30 | 90 | 365

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

Corvus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2023	Linda Grais	Director	Buy	10,000	$2.45	$24,500.00	10,000
12/20/2022	William Benton Jones	Insider	Buy	20,000	$0.79	$15,800.00	133,773
12/13/2022	Leiv Lea	CFO	Buy	30,000	$0.74	$22,200.00	129,238
12/13/2022	Richard A. Miller	CEO	Buy	50,000	$0.74	$37,000.00	1,480,119
9/28/2022	Richard A. Miller	CEO	Buy	25,000	$0.76	$19,000.00	1,394,405
9/20/2022	Richard A. Miller	CEO	Buy	20,000	$0.81	$16,200.00	1,369,405
6/27/2022	Richard A. Miller	CEO	Buy	5,000	$1.00	$5,000.00	1,349,405
6/24/2022	Richard A. Miller	CEO	Buy	5,000	$1.03	$5,150.00	1,344,405
6/6/2022	Richard A. Miller	CEO	Buy	890	$1.01	$898.90	1,339,405
6/2/2022	Richard A. Miller	CEO	Buy	5,000	$0.98	$4,900.00	1,338,515
3/31/2022	Richard A. Miller	CEO	Buy	15,000	$1.64	$24,600.00
3/17/2022	Richard A. Miller	CEO	Buy	5,000	$1.59	$7,950.00
3/16/2022	Leiv Lea	CFO	Buy	35,160	$1.54	$54,146.40
3/15/2022	Richard A. Miller	CEO	Buy	25,000	$1.47	$36,750.00
9/30/2021	Ecor1 Capital, Llc	Major Shareholder	Sell	3,000,000	$5.04	$15,120,000.00
9/20/2021	Orbimed Advisors Llc	Director	Sell	1,109,644	$6.09	$6,757,731.96
8/20/2021	Richard A. Miller	CEO	Buy	10,000	$1.93	$19,300.00	35,714

Did You Get Your Free Bitcoin Yet?

From Crypto Swap Profits | Ad

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

SEC Filings (Institutional Ownership Changes) for Corvus Pharmaceuticals (NASDAQ:CRVS)

46.64% of Corvus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Corvus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/1/2024	Towerview LLC	436,873	$0.77M	0.5%	+27.6%	0.891%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	70,883	$0.10M	0.0%	-16.0%	0.145%
11/4/2023	Towerview LLC	342,478	$0.50M	0.3%	+67.1%	0.699%
9/8/2023	Tucker Asset Management LLC	12,871	$29K	0.0%	N/A	0.026%
8/22/2023	CHI Advisors LLC	200,000	$0.46M	0.1%	-91.5%	0.408%
8/11/2023	MYDA Advisors LLC	100,000	$0.23M	0.1%	N/A	0.204%
8/7/2023	Acadian Asset Management LLC	58,069	$0.13M	0.0%	-55.9%	0.125%
8/3/2023	Towerview LLC	205,000	$0.47M	0.3%	N/A	0.440%
7/27/2023	Virtu Financial LLC	25,542	$58K	0.0%	+32.0%	0.055%
5/11/2023	CHI Advisors LLC	2,339,402	$2.13M	0.6%	-1.9%	5.024%
2/14/2023	Discovery Capital Management LLC CT	548,727	$0.47M	0.1%	N/A	1.179%
11/17/2022	Telemetry Investments L.L.C.	522,009	$0.43M	0.5%	+13.5%	1.121%
10/18/2022	Bailard Inc.	39,998	$33K	0.0%	N/A	0.086%
4/20/2022	Jackson Square Capital LLC	63,773	$0.11M	0.0%	N/A	0.137%
4/13/2022	Hikari Power Ltd	49,959	$82K	0.0%	+150.3%	0.107%
2/15/2022	Coastal Bridge Advisors LLC	24,000	$58K	0.0%	N/A	0.052%
2/14/2022	Point72 Asset Management L.P.	795,000	$1.92M	0.0%	+38.3%	1.708%
2/10/2022	Acadian Asset Management LLC	81,166	$0.19M	0.0%	+96.9%	0.174%
11/22/2021	EcoR1 Capital LLC	2,081,077	$10.07M	0.4%	-41.9%	4.471%
11/16/2021	Squarepoint Ops LLC	19,954	$97K	0.0%	N/A	0.043%
11/16/2021	Tang Capital Management LLC	3,749,379	$18.15M	3.8%	N/A	8.055%
11/16/2021	Two Sigma Investments LP	140,455	$0.68M	0.0%	-54.6%	0.302%
11/16/2021	Two Sigma Securities LLC	22,789	$0.11M	0.0%	N/A	0.049%
11/16/2021	Telemetry Investments L.L.C.	196,168	$0.95M	1.3%	-25.7%	0.421%
11/16/2021	VR Adviser LLC	3,427,461	$16.59M	2.1%	N/A	7.363%
11/16/2021	BVF Inc. IL	1,370,947	$6.64M	0.3%	-62.7%	2.945%
11/16/2021	CHI Advisors LLC	165,927	$0.80M	0.2%	-76.9%	0.356%
11/15/2021	Point72 Asset Management L.P.	575,000	$2.78M	0.0%	N/A	1.235%
11/15/2021	Pura Vida Investments LLC	734,268	$3.55M	0.1%	N/A	1.577%
11/15/2021	Zacks Investment Management	10,000	$48K	0.0%	N/A	0.021%
11/12/2021	Affinity Asset Advisors LLC	50,000	$0.24M	0.1%	N/A	0.107%
11/12/2021	Renaissance Technologies LLC	614,370	$2.97M	0.0%	-6.6%	1.320%
11/12/2021	DC Investments Management LLC	50,709	$0.25M	0.5%	N/A	0.109%
11/12/2021	MYDA Advisors LLC	60,000	$0.29M	0.1%	N/A	0.129%
11/12/2021	Geode Capital Management LLC	210,243	$1.02M	0.0%	+10.9%	0.452%
11/12/2021	Artal Group S.A.	500,000	$2.42M	0.1%	N/A	1.074%
11/9/2021	BlackRock Inc.	100,451	$0.49M	0.0%	-23.3%	0.216%
11/5/2021	Lindbrook Capital LLC	14,000	$68K	0.0%	N/A	0.033%
8/17/2021	BVF Inc. IL	3,678,626	$9.82M	0.4%	+13.9%	8.672%
8/16/2021	Telemetry Investments L.L.C.	263,975	$0.71M	1.0%	+6.0%	0.622%
8/16/2021	State Street Corp	29,600	$79K	0.0%	N/A	0.070%
8/13/2021	Renaissance Technologies LLC	658,070	$1.76M	0.0%	-0.8%	1.551%
8/13/2021	Northern Trust Corp	59,262	$0.16M	0.0%	+56.5%	0.140%
8/13/2021	Laurion Capital Management LP	59,150	$0.16M	0.0%	-79.0%	0.139%
8/13/2021	Algert Global LLC	19,737	$53K	0.0%	-53.9%	0.047%
8/13/2021	Natixis	27,900	$74K	0.0%	+69.1%	0.066%
8/13/2021	Geode Capital Management LLC	189,541	$0.51M	0.0%	+27.4%	0.447%
8/13/2021	Vanguard Group Inc.	1,109,218	$2.96M	0.0%	+10.9%	2.615%
8/12/2021	Dimensional Fund Advisors LP	395,829	$1.06M	0.0%	-5.0%	0.933%
8/11/2021	CHI Advisors LLC	719,132	$1.92M	0.4%	+5.9%	1.695%
5/18/2021	BVF Inc. IL	3,229,426	$9.95M	0.4%	+66.1%	8.430%
5/18/2021	Millennium Management LLC	99,096	$0.31M	0.0%	-18.5%	0.259%
5/18/2021	Orbimed Advisors LLC	8,053,298	$24.80M	0.2%	+19.0%	21.021%
5/17/2021	Ikarian Capital LLC	100,000	$0.31M	0.0%	N/A	0.261%
5/17/2021	Goldman Sachs Group Inc.	30,804	$95K	0.0%	-62.3%	0.080%
5/14/2021	Laurion Capital Management LP	282,132	$0.87M	0.0%	N/A	0.736%
5/14/2021	Dimensional Fund Advisors LP	416,649	$1.28M	0.0%	-4.5%	1.088%
5/14/2021	Algert Global LLC	42,857	$0.13M	0.0%	+177.1%	0.112%
5/13/2021	Renaissance Technologies LLC	663,470	$2.04M	0.0%	-16.8%	1.732%
5/12/2021	Northern Trust Corp	37,878	$0.12M	0.0%	+28.6%	0.099%
5/12/2021	Geode Capital Management LLC	148,834	$0.46M	0.0%	+34.5%	0.388%
5/11/2021	Mercer Global Advisors Inc. ADV	10,500	$32K	0.0%	N/A	0.027%
5/11/2021	Acadian Asset Management LLC	20,936	$64K	0.0%	-77.4%	0.055%
5/10/2021	GSA Capital Partners LLP	95,613	$0.29M	0.0%	N/A	0.250%
5/10/2021	Bank Julius Baer & Co. Ltd Zurich	336,748	$1.04M	0.0%	N/A	0.879%
5/7/2021	BlackRock Inc.	77,668	$0.24M	0.0%	+11.3%	0.203%
5/4/2021	Envestnet Asset Management Inc.	10,500	$32K	0.0%	N/A	0.027%
2/18/2021	Truist Financial Corp	21,000	$75K	0.0%	N/A	0.075%
2/12/2021	CHI Advisors LLC	490,877	$1.75M	0.5%	-15.8%	1.749%
2/10/2021	Renaissance Technologies LLC	797,070	$2.84M	0.0%	-8.9%	2.840%
2/5/2021	BlackRock Inc.	69,810	$0.25M	0.0%	-56.8%	0.249%
1/25/2021	Golden Green Inc.	19,539	$70K	0.1%	N/A	0.070%
11/13/2020	Morgan Stanley	32,746	$0.13M	0.0%	+117.7%	0.117%
11/9/2020	Acadian Asset Management LLC	157,134	$0.63M	0.0%	-13.5%	0.560%
11/6/2020	BlackRock Inc.	161,549	$0.65M	0.0%	-48.0%	0.576%
10/8/2020	Hikari Power Ltd	19,959	$80K	0.0%	-67.3%	0.071%
9/15/2020	Two Sigma Advisers LP	36,880	$100K	0.0%	+27.7%	0.132%
8/14/2020	BVF Inc. IL	1,742,112	$4.74M	0.3%	-19.2%	6.214%
8/5/2020	Russell Investments Group Ltd.	39,171	$0.11M	0.0%	+29.6%	0.140%
5/15/2020	Squarepoint Ops LLC	24,436	$52K	0.0%	N/A	0.087%
5/15/2020	Morgan Stanley	32,920	$69K	0.0%	-14.8%	0.118%
5/15/2020	Two Sigma Investments LP	99,258	$0.21M	0.0%	-8.6%	0.355%
5/15/2020	Two Sigma Advisers LP	28,880	$61K	0.0%	+74.2%	0.103%
5/13/2020	Connor Clark & Lunn Investment Management Ltd.	85,604	$0.18M	0.0%	+4.7%	0.306%
5/6/2020	Russell Investments Group Ltd.	30,220	$63K	0.0%	N/A	0.108%
2/20/2020	Geode Capital Management LLC	137,555	$0.75M	0.0%	+6.3%	0.468%
2/14/2020	Bank of America Corp DE	22,811	$0.12M	0.0%	-51.9%	0.078%

Data available starting January 2016

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Today's Range

Now: $1.45

$1.41

$1.49

50 Day Range

MA: $1.90

$1.36

$2.36

52 Week Range

Now: $1.45

$0.98

$4.19

Volume

11,671 shs

Average Volume

201,768 shs

Market Capitalization

$71.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of Corvus Pharmaceuticals?: Corvus Pharmaceuticals' top insider shareholders include:
Richard A Md Miller (CEO)
William Benton Jones (Insider)
Leiv Lea (CFO)
Linda Grais (Director)
Learn More about top insider investors at Corvus Pharmaceuticals.